person · Reporting owner
van Dijk Marcus Antonius
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiNK Therapeutics, Inc.INKT · Entity 52 | Chief Scientific Officer | January 16, 2024 | January 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiNK Therapeutics, Inc.
Report date January 16, 2024 · Filed January 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2034-01-16 | Direct | 15,000 |
Reported balance
After 2024-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-16 · Grant · Acquired 15,000 · Balance 15,000 F1: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2034-01-16 | Direct | 171,078 |
Reported balance
After 2024-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-16 · Grant · Acquired 171,078 · Balance 171,078 F2: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
F2: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2024 Filed Jan 18, 2024 20:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option · Derivative | 171,078 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0000950170-24-005561 · ownership.xml · derivative · entry 2 van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,078 Underlying: Common Stock · 171,078 shares Expires 2034-01-16 F2 · derivative.exercise_date: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0000950170-24-005561 · ownership.xml · derivative · entry 1 van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-01-16 F1 · derivative.exercise_date: An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 17:26 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0000899243-23-001622 · doc4.xml · derivative · entry 1 van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-01-09 F1 · derivative.exercise_date: Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 10:48 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | Tax withholdingCommon Stock | 24,265 | $2.32 | $56,294.80 |
DisclosureSEC source: 0000899243-23-001660 · doc4.xml · nonDerivative · entry 2 van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,363 F3 · price: Represents payment of tax liability by withholding shares of common stock incident to the vesting of stock. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 10:48 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 51,628 | $2.32 | $119,776.96 |
DisclosureSEC source: 0000899243-23-001660 · doc4.xml · nonDerivative · entry 1 van Dijk Marcus Antonius · CIK 0001881659 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,628 F1 · security: Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023. F2 · price: $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 17:19 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0000899243-22-003171 · doc4.xml · derivative · entry 1 van Dijk Marcus Antonius · CIK 0001881659 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-01-21 F1 · derivative.exercise_date: Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.